Santovia Path AI and FUJIFILM Healthcare Announce Partnership to Advance AI-Powered Pathology Workflows

Collaboration aims to bring in market SAINT, the AI powered SantoviaPath Platform into Fujifilm's Synapse Pathology solutions package offered to Fujifilm's global network of clients.

Boston MA , Lexington, MA — October 26, 2026— Santovia Path AI, a developer of artificial intelligence tools for digital pathology, today announced a partnership with FUJIFILM Healthcare to advance the use of AI in pathology workflows. The collaboration brings together Santovia's expertise in AI-powered image analysis and Fujifilm's experience in digital pathology, with a shared goal of making pathology workflows more efficient while keeping pathologists at the center of interpretation.

Santovia's SAINT platform initially focuses on colorectal tissue specimens, trained with longitudinal data of whole-slide images to identify cases that appear normal and flag those that warrant further evaluation. This approach is designed to support case prioritization and streamline review.

"Our goal was never simply to build another AI algorithm. We wanted to take great science out of the research environment and put it into the hands of pathologists, where it can ultimately make a difference for patients. Seeing SAINT move so quickly from research to a commercial partnership with Fuji Healthcare shows what can happen when academic innovation and industry come together with a common purpose," said Alexander Kouspakian, Chief Executive Officer of Santovia Path AI.

"The value of digital pathology grows when we connect image access with tools that help pathologists act on information," said Dr. Mark Lloyd, VP of Pathology at FUJIFILM Healthcare. "Partnering with Santovia offers an opportunity to explore how AI-assisted tools can support more efficient workflows while preserving the expertise and judgment essential to pathology."

SAINT is currently offered for research use. Deployment in clinical laboratory environments requires independent institutional validation in accordance with applicable regulatory requirements. The platform supports analysis and workflow; final diagnostic decisions remain with qualified medical professionals.

To learn more about SantoviaPath Ai and SAINT or request a demonstration, please visit santoviapath.ai.

About Santovia

Santovia develops AI-powered tools for digital pathology analysis and research. Its SAINT platform combines image analysis, clinical information, and human verification to support case prioritization and laboratory workflows. Founded on research and real-world healthcare data, Santovia brings together expertise in artificial intelligence, pathology, and healthcare to advance computational pathology.

About FUJIFILM Healthcare

FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis, and treatment of diseases. Fujifilm's innovative portfolio includes solutions spanning diagnostic imaging, enterprise imaging, endoscopic imaging, surgical imaging, and in-vitro diagnostics. The Non-Destructive Testing group delivers radiography solutions to ensure high accuracy inspection of transportation infrastructure, and assets within aerospace, and oil and gas industries. The company is headquartered in Lexington, Massachusetts. For more information on healthcare offerings, please visit healthcaresolutions-us.fujifilm.com, and for NDT portfolio, please visit https://www.fujifilm.com/us/en/business/industrial-materials/non-destructive-testing.

FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit: https://holdings.fujifilm.com/en.